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Abstract
Background: The objective of this study was to evaluate the efficacy of atomoxetine, a new and
highly selective inhibitor of the norepinephrine transporter, in reducing symptoms of attention-
deficit/hyperactivity disorder (ADHD) among adults by using drug-placebo response curve
methods.
Methods: We analyzed data from two double-blind, placebo-controlled, parallel design studies of
adult patients (Study I, N = 280; Study II, N = 256) with DSM-IV-defined ADHD who were recruited
by referral and advertising. Subjects were randomized to 10 weeks of treatment with atomoxetine
or placebo, and were assessed with the Conners Adult ADHD Rating Scales and the Clinical Global
Impression of ADHD Severity scale before and after treatment.
Results:  Those treated with atomoxetine were more likely to show a reduction in ADHD
symptoms than those receiving placebo. Across all measures, the likelihood that an atomoxetine-
treated subject improved to a greater extent than a placebo-treated subject was approximately
0.60. Furthermore, atomoxetine prevented worsening of most symptom classes.
Conclusion: From these findings, we conclude that atomoxetine is an effective treatment for
ADHD among adults when evaluated using several criteria.
Introduction
Several compounds are now recognized as effective treat-
ments for the major symptoms of attention-deficit/hyper-
activity disorder (ADHD) in adulthood. The most
effective of these include methylphenidate and dextroam-
phetamine (or mixed dextro- and levoamphetamine);
however, the use of other agents, such as bupropion and
desipramine, has also received some support. In addition
to these, atomoxetine, a highly selective noradrenergic
reuptake inhibitor with little affinity for other neurotrans-
mitter systems [1], has been shown to be well tolerated
and effective in reducing the symptoms of ADHD in
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adulthood. In fact, the benefits of atomoxetine for adults
with ADHD have now been demonstrated in three studies
of adult patients [2,3], with each report establishing the
superiority of atomoxetine over placebo in reducing inat-
tentive, hyperactive, and impulsive symptoms of the ill-
ness [3]. As a result of its demonstrated efficacy and low
occurrence of clinically meaningful side effects [4], atom-
oxetine recently became the first non-stimulant medica-
tion approved for use in the United States for the
treatment of ADHD in adults.
Thus, the ability of atomoxetine to reduce symptoms of
ADHD among adults has been sufficiently established;
however, several key questions about its clinical utility
remain unresolved. For example, although the initial
studies of the efficacy of atomoxetine provided useful
information for clinicians treating adults with ADHD,
such as the average magnitude of the decrease in ADHD
symptoms associated with drug treatment and the reliabil-
ity of this effect, the standard methods of data presenta-
tion in these reports do not provide information about
the full range of effects of this compound. To further char-
acterize the clinical performance of atomoxetine, we com-
pleted a drug-placebo response curve analysis of the data
initially reported by Michelson et al. [3] This method,
described by Faraone et al. [5], is a generalization of
receiver operating characteristic (ROC) analysis [6], which
has been widely applied to assessing the accuracy of diag-
nostic tests [7-9]. The goal of this method is to identify
additional characteristics of drug-placebo differences that
have already been shown to be statistically significant,
including: 1) the size of the effect using different response
criteria; 2) the nature of individual responses; and 3) the
portion of the drug's effect that is due to symptom
improvement, the prevention of symptom worsening, or
both.
Results
Standard Analyses
To provide a foundation for interpreting the results of
drug-placebo response curve analysis of the effects of ato-
moxetine, we have displayed in Table 1 a summary of
results of the standard analyses of these data, which were
originally presented by Michelson et al. [3]. Although data
on clinical global impression (CGI) endpoints or Conners
Adult ADHD Rating Scale (CAARS) ADHD index scores
were not presented in the initial report, it is clear that ato-
moxetine had significant efficacy relative to placebo on all
other measures derived from the CAARS or CGI assess-
ments. The most reliable reductions in ADHD symptoms
elicited by atomoxetine were seen for clinician-rated glo-
bal impressions of ADHD severity, and investigator- and
self-rated total ADHD symptoms. Atomoxetine more
robustly reduced inattentiveness than hyperactivity and
impulsivity, as assessed by both investigators and sub-
jects. Overall, these data provided strong and conclusive
evidence that atomoxetine was superior to placebo in
reducing the symptoms of ADHD in adulthood, warrant-
ing further analysis by drug-placebo response curve
methods.
CAARS Investigator Ratings
Figures 1, 2, 3, 4 show the results for investigator ratings
on the CAARS. Figure 1 compares the effects of atomoxet-
ine on total ADHD score with those of placebo. For differ-
ent definitions of responsiveness (i.e., different CAARS
cutting scores), the points on the curve illustrate the
results of two calculations: the rate of response to drug
and the rate of response to placebo. For example, the
point in Figure 1 labeled -7 is located at coordinates [0.4,
0.54], which indicates that 40% of those treated with pla-
cebo achieved a change of -7 in total investigator-rated
ADHD symptoms on the CAARS, whereas 54% of those
Table 1: Summary of Effects of Atomoxetine and Placebo on ADHD Symptoms in Adults*
Study I Study II
Placebo (n = 134) Atomoxetine (n = 133) p Placebo (n = 124) Atomoxetine (n = 124) p
CGI Change Score -0.4 ± 1.0 -0.8 ± 1.2 0.010 -0.5 ± 1.0 -0.9 ± 1.2 0.002
Investigator-Rated CAARS
Total ADHD Symptom Scores -6.0 ± 9.3 -9.5 ± 10.1 0.005 -6.7 ± 9.3 -10.5 ± 10.9 0.002
Inattentive Score -3.1 ± 5.8 -5.0 ± 5.7 0.010 -3.5 ± 5.3 -5.8 ± 6.5 0.001
Hyperactive/Impulsive Score -2.9 ± 4.9 -4.5 ± 5.1 0.017 -3.2 ± 4.7 -4.7 ± 5.3 0.013
Self-Rated CAARS
Total ADHD Symptom Score -9.3 ± 14.0 -16.0 ± 16.2 0.002 -11.6 ± 16.1 -17.3 ± 17.6 0.008
Inattentive Score -8.6 ± 13.8 -15.9 ± 16.3 0.001 -11.3 ± 16.6 -17.1 ± 17.9 0.012
Hyperactive/Impulsive Score -7.5 ± 12.1 -11.9 ± 13.5 0.013 -8.8 ± 13.4 -12.5 ± 14.1 0.025
*Data adapted from Michelson et al., 2003
Data are presented as mean ± standard deviationBehavioral and Brain Functions 2005, 1:16 http://www.behavioralandbrainfunctions.com/content/1/1/16
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treated with atomoxetine attained the same level of
responsiveness. Sequential points further down the curve
(i.e., toward the origin) specify increasingly stringent
thresholds for defining improvement (i.e., larger
decreases in investigator-rated total ADHD score), while
points further up the curve denote the proportions of each
treatment group that responded to treatment as deter-
mined by increasingly lenient criteria for improvement.
Thus, these points and the curve that joins them illustrate
how the drug- and placebo-response rates change as the
cutting score used to define improvement is incrementally
changed. From the curve, it is clear that if response criteria
between total ADHD symptom change scores of -1 and -
14 are used as the cutting score, a greater proportion of
atomoxetine-treated individuals than placebo-treated
patients will attain that level of symptom improvement.
In other words, over this range of cutting scores, the
majority of individuals judged as responsive to treatment
will have received atomoxetine rather than placebo. Near
the most extreme cutting scores (in this case, the points
labeled 15 and -46), those treated with placebo were as
likely as those treated with atomoxetine to reach response
criteria.
Figure 1 (and each figure) also shows the diagonal line of
no effect, which allows us to visualize the size of the drug
effect as the degree to which the drug-placebo response
curve rises above it. If outcome on drug were worse than
outcome on placebo, then the drug-placebo response
curve would fall below the line of no effect; however, as
Figure 1 shows, atomoxetine produced a drug-placebo
response curve that was always above the diagonal line of
no effect. This indicates that atomoxetine outperformed
placebo throughout the full range of outcome scores. The
area under the curve (AUC) is 0.60, which means that ato-
moxetine outperformed placebo 60 percent of the time,
regardless of cutting score.
In addition to this information, and unlike a traditional
statistical analysis, Figure 1 also allows us to determine if
the effects of atomoxetine were due to its ability to
improve the symptoms of ADHD, prevent their worsen-
ing, or both. For example, for CAARS total ADHD symp-
tom change scores, a value of 0 indicates no change, and
this point on the drug-placebo response curve is labeled.
At this point on the curve, we see that 82% of subjects
receiving atomoxetine had a score of 0 or greater, i.e., only
18% of atomoxetine-treated patients experienced a wors-
CAARS Investigator-Rated Total ADHD Score Figure 1
CAARS Investigator-Rated Total ADHD Score.Behavioral and Brain Functions 2005, 1:16 http://www.behavioralandbrainfunctions.com/content/1/1/16
Page 4 of 12
(page number not for citation purposes)
ening of their symptoms. In contrast, 71% of placebo-
treated subjects had a score of 0 or greater, which indicates
that symptoms worsened in 29% of these patients. Thus,
the response curve clearly demonstrates that atomoxetine
not only reduced symptoms, but prevented their worsen-
ing as well.
Figure 2 illustrates the effects of atomoxetine on investiga-
tor-rated inattention on the CAARS. As with total ADHD
symptoms, inattentive symptoms seem to be more effec-
tively treated by atomoxetine than placebo, as the drug-
placebo response curve was above the diagonal line of no
effect and the AUC was 0.61. Relative to total ADHD
symptoms, there exists for inattention a narrower range of
cutting scores over which the greatest difference in respon-
siveness was seen between atomoxetine- and placebo-
treated subjects. At cutting scores of -4 through -8, approx-
imately 50% more atomoxetine-treated subjects reached
the response criterion than did placebo-treated subjects.
Figure 3 shows the effects of atomoxetine and placebo on
investigator-rated hyperactivity on the CAARS. Relative to
Figure 2 (inattention), the drug-placebo response curve in
Figure 3 did not rise as far above the diagonal line of no
effect and, consequently, the AUC for hyperactivity (0.58)
was lower than that for inattention (0.61). These results
indicate that atomoxetine was less effective in reducing
(and preventing the worsening of) hyperactivity than in
improving attention. However, it is still clear that, relative
to placebo, atomoxetine was an effective treatment for
hyperactivity when any symptom change score criteria of
less than 0 was used as the response criterion.
In Figure 4, the effects of atomoxetine and placebo on
investigator-rated ADHD index scores are plotted, and the
more restricted rise in this curve is immediately apparent
relative to that seen in earlier figures. The AUC for this
curve (0.59) was significant (p < 0.001), indicating that
atomoxetine was more likely than placebo to reduce the
ADHD index score. However, there is a distinct peak in
this curve at a response criterion of approximately -8,
where atomoxetine-treated subjects were approximately
twice as likely as placebo-treated subjects to attain this
level of symptom improvement; at other cutting scores
(e.g., -3), the benefits of atomoxetine were much more
modest.
CAARS Self Ratings
Figures 5, 6, 7, 8, illustrate the results for self-ratings on
the CAARS. In general, the effects of atomoxetine on self-
CAARS Investigator-Rated Inattention Subscale Figure 2
CAARS Investigator-Rated Inattention Subscale.Behavioral and Brain Functions 2005, 1:16 http://www.behavioralandbrainfunctions.com/content/1/1/16
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ratings on the CAARS mirrored its effects on investigator
ratings. From Figure 5 it is clear that, as with investigator-
ratings of this measure, self-rated total ADHD symptoms
were more likely to be reduced in atomoxetine-treated
subjects than in those receiving placebo. In fact, the AUC
for this measure (0.61) was virtually identical to that
observed on investigator ratings of this measure, and ben-
eficial effects of atomoxetine were observed over roughly
the same range of cutting scores. More than 60% of sub-
jects treated with atomoxetine attained the median
response score (-6), while only approximately 40% of
those treated with placebo saw this level of improvement;
thus, when the median response score was used as the cut-
ting score for defining responsiveness, atomoxetine had
greater efficacy on self reported total ADHD symptoma-
tology than on investigator ratings of this measure (cf, Fig-
ure 1).
The shape and position of the drug-placebo response
curve for self-rated CAARS inattention change scores (Fig-
ure 6) was quite similar to the curve for investigator rat-
ings of this measure (Figure 2). Specifically, the curve was
above the diagonal line of no effect and had a significant
AUC, indicating that atomoxetine administration was
more effective than placebo in reducing inattentive symp-
toms. Of note, the drug-response curve for self-ratings of
hyperactivity very closely matched that for investigator-
ratings of this measure (Figure 7), indicating an apprecia-
ble amount of divergence in subjects' perceptions of the
effects of treatment on their constituent symptom clusters.
As expected, self-rated ADHD index change scores
mirrored investigator ratings in showing a sizeable benefit
of atomoxetine over placebo, especially when symptom
change scores in the range of -4 to -9 were used as
response criteria (Figure 8).
CGI Clinician Ratings
Figure 9 depicts the effects of atomoxetine and placebo on
ADHD symptom severity change scores for the CGI. As
with the CAARS measures, the drug-placebo response
curve occupied the space above the diagonal line of no
effect and the AUC approximated 0.60, indicating an
advantage of atomoxetine over placebo in reducing clini-
cian-rated ADHD severity. Also in accord with the CAARS
measures, a small protection from symptom worsening
was afforded by atomoxetine, as approximately 10% of
subjects who received the drug deteriorated clinically,
while approximately twice as many placebo-treated
CAARS Investigator-Rated Hyperactive Subscale Figure 3
CAARS Investigator-Rated Hyperactive Subscale.Behavioral and Brain Functions 2005, 1:16 http://www.behavioralandbrainfunctions.com/content/1/1/16
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subjects did so. The median change in CGI in the com-
bined group of atomoxetine- and placebo-treated subjects
was -1, a response criterion attained by almost 55% of
drug-treated subjects but by only approximately 40% of
those receiving placebo. As expected, these greater rates of
improvement (and protection from deterioration) led to
the attainment of lower CGI endpoint scores in the atom-
oxetine-treated group (Figure 10).
Discussion
The results of two large randomized, double-blind, pla-
cebo-controlled trials of atomoxetine for the treatment of
ADHD in adults were initially reported by Michelson et al.
[3], who documented the superiority of this compound
relative to placebo in reducing total ADHD symptoms, as
well as inattentive and hyperactive symptoms of the ill-
ness. Due to the ample size and rigorous design of these
studies, as well as the strong statistical significance of their
results, the efficacy of atomoxetine has been firmly estab-
lished. However, the simple knowledge that, on average,
atomoxetine is efficacious does not tell clinicians much
about its full range of effect.
Drug-placebo response curves provide an easily interpret-
able format for further evaluating clinically informative
characteristics of a compound with proven efficacy.
Because atomoxetine has demonstrable efficacy, drug-pla-
cebo response curve analysis of its performance against
placebo was warranted. Collectively, the drug-placebo
response curves presented here for each of the different
reporters and the various dependent measures paint a
consistent picture of the benefits of atomoxetine. First, it
is clear that atomoxetine is superior to placebo in reduc-
ing total ADHD symptoms as well as individual symptom
clusters, such as inattention and hyperactivity. For each of
these measures, the drug-placebo response curve was
always situated above the line of no effect, indicating that
subjects were more likely to respond to atomoxetine than
to placebo over the entire range of possible criteria of
responsiveness. In addition, it is clear that atomoxetine
targeted the core features of ADHD rather than only one
of its most conspicuous features of inattention and hyper-
activity, as AUCs across total, inattention, and
hyperactivity change scores were quite similar. Second,
responsiveness to atomoxetine was reliably assessed by
CAARS Investigator-Rated ADHD Index Figure 4
CAARS Investigator-Rated ADHD Index.Behavioral and Brain Functions 2005, 1:16 http://www.behavioralandbrainfunctions.com/content/1/1/16
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clinicians, investigators, and patients, as the AUCs for the
various dependent measures varied little (0.58–0.61)
across reporters. Third, atomoxetine not only reduced the
symptoms of ADHD, but prevented the worsening of
these symptoms as well, a finding that has been seen for
drug-placebo response curve analyses of other medica-
tions [5,10,11]. In contrast however, these prior drug-pla-
cebo response curve analyses have also revealed stronger
effects of other medications on clinician-rated ADHD
symptomatology, as evidenced by AUCs of 0.86 for
Adderall [5,10,11], 0.89 for methylphenidate [5,10,11],
and 0.93 for desipramine [5,10,11], as compared to the
AUC of approximately 0.60 presently observed for
atomoxetine.
In conclusion, we have extended the statistical results of
Michelson et al. [3] by using drug-placebo response curves
to describe the clinical significance of the efficacy of ato-
moxetine in the treatment of ADHD among adults. Our
method of data presentation provides readers and clini-
cians with a means of understanding the nature of the
effects of this drug, and the degree to which they are clin-
ically relevant. Rather than collapsing individual
responses into means or single rates of response, the drug-
placebo response curve illustrates clinically meaningful
details that often are lost in a standard analysis, such as
the ability of atomoxetine to improve outcome and
prevent worsening throughout the full range of outcome
scores. The present drug-placebo response analysis
provided strong support for the efficacy of atomoxetine
relative to placebo for reducing inattention, hyperactivity,
and total ADHD symptoms assessed by a variety of
reporters, and for preventing the worsening of these
symptoms. The finding that atomoxetine is efficacious
through the full range of outcome further emphasizes the
clinical value of treating ADHD adults with this
medication.
Methods
Subjects
Two identical randomized, double-blind, placebo-con-
trolled studies were conducted concurrently at 17 (Study
I) and 14 (Study II) outpatient sites in North America.
Each site's institutional review board evaluated and
approved the study protocol, and written informed con-
sent was obtained from each patient. Adults who met
DSM-IV criteria for ADHD as assessed by clinical inter-
view and confirmed by the Conners' Adult ADHD Diag-
nostic Interview for DSM-IV were recruited from clinics
and by advertisement. Patients were required to have at
CAARS Self-Rated Total ADHD Score Figure 5
CAARS Self-Rated Total ADHD Score.Behavioral and Brain Functions 2005, 1:16 http://www.behavioralandbrainfunctions.com/content/1/1/16
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least moderate symptom severity, and the diagnosis had
to be corroborated by a second reporter for either current
symptoms (by a significant other) or childhood symp-
toms (by a parent or older sibling). Patients who met
diagnostic criteria for any other Axis-I disorder using the
Structured Clinical Interview for DSM-IV were excluded,
as were patients with serious medical illness or habitual
substance abuse.
Atomoxetine and Placebo Administration
Following an initial one-week medication washout and
evaluation period, patients entered a two-week placebo
lead-in phase. Patients who maintained the initial severity
criteria required for study entry were randomized to
receive atomoxetine or placebo for a 10-week period. Ato-
moxetine was administered in evenly divided doses in the
morning and late afternoon/early evening beginning at a
total daily dose of 60 mg. Patients with residual symp-
toms received higher doses of up to 90 mg/day after two
weeks and 120 mg/day after four weeks. If patients devel-
oped problems tolerating this regimen, the dose could be
decreased to the last tolerated dose or an increase in dos-
age could be omitted. Across both studies, 270 subjects
received atomoxetine, while 263 subjects received pla-
cebo. Of these, 197 completed acute treatment with atom-
oxetine, while 211 placebo-treated subjects completed the
trial, a difference that was not significant.
Outcome Measures
The outcome measures examined in this study were
derived from the CAARS and the CGI. A clinician com-
pleted the CGI before and after the treatment regimen,
while both the subject and an investigator completed the
CAARS before and after treatment. The three groups of pri-
mary dependent measures of this study included: 1.) cli-
nician-rated CGI ADHD Severity change scores and
endpoint scores; 2.) investigator-rated inattention, hyper-
activity/impulsivity, total symptoms, and ADHD index
scores on the CAARS; and 3.) self-rated inattention,
hyperactivity/impulsivity, total symptoms, and ADHD
index scores on the CAARS.
Drug-Placebo Response Curve Analysis
The rationale and methodology for drug-placebo
response curve analysis methods are described in detail by
Faraone et al. [5] The goal of response curve analysis is not
to demonstrate statistically significant group differences;
rather, this method provides an alternative means of dis-
playing differences that have already been demonstrated
to be statistically significant. Thus, it does not replace a
CAARS Self-Rated Inattention Subscale Figure 6
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standard statistical analysis, but augments that analysis by
showing the clinical significance of drug effects. For the
present study, the use of drug-placebo response curve
analysis is warranted, as the statistically significant effects
of atomoxetine on reducing symptoms of ADHD in adults
have been documented previously.
The drug-placebo response curve is constructed in the fol-
lowing six steps: 1.) Choose an outcome variable, for
example the change in CAARS Inattention score from
baseline to the end of the study; 2.) At each observed
score, calculate separately for the drug and placebo groups
the proportion of subjects having that score or a better
score. For CAARS change scores, therapeutic change is
indicated by negative numbers, i.e., a decrease in the
symptom score; 3.) For each observed score, plot these
proportions for the drug group on the vertical axis against
the proportions computed for the placebo group on the
horizontal axis; 4.) Connect the plotted points and label
those that correspond to the best response, the 25th per-
centile of response, the median response, the 75th percen-
tile of response and the worst response; 5.) If the outcome
variable is a change score, also label the point correspond-
ing to no change; 6.) Plot the line of no effect, which is the
diagonal line from the [0, 0] point to the [1,1] point. Each
point along a curve represents an observed outcome score
on that measure, and the points on each plot are then con-
nected by line segments. The line of no effect comprises all
points for which the proportion of subjects who respond
to drug is the same as the proportion who respond to
placebo.
The drug-placebo response curve is a graphical method of
describing results from a clinical trial, not a statistical test.
It is most sensibly used to describe an effect that has been
demonstrated with appropriate statistical tools. Neverthe-
less, the drug-placebo response curve's roots in (ROC)
analysis motivate the computation of one statistic, the
AUC, which is computed through integration. The area
under the drug-placebo response curve ranges from 0.5
(when the drug effect equals the placebo effect) to 1.0
(when the drug is completely effective and the placebo
has no effect). The AUC is a useful index of clinical signif-
icance because it equals the probability that a randomly
CAARS Self-Rated Hyperactive Subscale Figure 7
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selected member of the drug group will have a better
result than a randomly selected member of the placebo
group [12,13], i.e., the probability that drug will outper-
form placebo.
In summary, the placebo-response curve provides four
pieces of clinically relevant data not typically available
from traditional statistical analyses of outcomes data.
First, the effect size of a drug on an outcome measure can
be determined as the distance between the curve and the
line of no effect at any given cut-point. Second, the ratio
of drug responders to placebo responders across the range
of outcomes can be determined as the area under the
curve. Third, the likelihood of a drug to elicit a specific
outcome (e.g., a clinically meaningful cut-point) can be
determined as the proportion of drug-responders to pla-
cebo-responders at any given cut-point. Fourth, the ability
of a drug to improve functioning vs. prevent worsening of
functioning can be determined as the proportion of drug-
responders to placebo-responders at the outcome score
representing no change.
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